fig6

Figure 6. UCMSC-NVs inhibit LPS-induced activation of the NF-κB/NLRP3 pathway in vitro. (A) The transcriptional activity of pro-inflammatory cytokines in MH-S cells was monitored by quantitative PCR a day after LPS administration; (B) The protein profiles of phosphorylated and total p65, as well as phosphorylated and total IκBα in MH-S cells pretreated with UCMSC-NVs for half an hour before encountering LPS, were assayed using western blot methods. followed by LPS stimulation for 24 h. n = 3 per group; Western blot assessment of NLRP3, Caspase-1, and IL-1β protein expression levels. n = 3 per group. Data represent means ± SD. Statistical analysis was performed by one-way ANOVA. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. UCMSC-NVs: Nanovesicles originating from human umbilical cord mesenchymal stem cells; LPS: lipopolysaccharide; NF-κB: nuclear factor κB; NLRP3: NOD-like receptor protein 3; PCR: polymerase chain reaction; IL-1β: interleukin-1β; SD: standard deviation; ANOVA: analysis of variance; mRNA: messenger RNA; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α; IFNγ: interferon-gamma; MMP-9: matrix metallopeptidase 9; GM-CSF: granulocyte-macrophage colony-stimulating factor; p-IκBα: phosphorylated IκBα.